Source: Eur Respir J 2003; 21: 260-266
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Sin D.D., Man S.F.P.. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter?. Eur Respir J 2003; 21: 260-266

Member's Comments

No comment yet.

Related content which might interest you: Inhaled corticosteroids and survival in chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 202-203 Year: 2003 Inhaled corticosteroids and hospitalisation due to exacerbation of COPD Source: Eur Respir J 2003; 22: 286-289 Year: 2003 Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004 What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Source: Eur Respir J 2002; 19: 928-935 Year: 2002 Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia Source: Eur Respir J 2010; 36: 751-757 Year: 2010 Audit of inhaled corticosteroid prescription in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2010 - COPD: management Year: 2010 Modern treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: 60S-66S Year: 2001 Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006 Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids Source: Eur Respir J 2001; 17: 337-342 Year: 2001 Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids Source: Annual Congress 2006 - COPD therapy Year: 2006 The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001 A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Source: Eur Respir J 2002; 19: 217-224 Year: 2002 Inhaled budesonide in the management of chronic obstructive pulmonary diseases Source: Eur Respir J 2002; 20: Suppl. 38, 244s Year: 2002 Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001 Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline Source: Annual Congress 2005 - Therapeutic options for COPD: present and future Year: 2005 Where current pharmacological therapies fall short in COPD: symptom control is not enough Source: Eur Respir Rev 2007; 16: 98-104 Year: 2007 The role of nebulised budesonide in the treatment of exacerbations of COPD Source: Eur Respir J 2007; 29: 660-667 Year: 2007 Low-dose inhaled and nasal corticosteroid use and the risk of cataracts Source: Eur Respir J 2006; 27: 1168-1174 Year: 2006 The efficacy and treatment length of oral corticosteroids in patient with acute exacerbation of chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 295s Year: 2005 Mechanism by which inhaled bronchodilators prevent exacerbations in chronic obstructive pulmonary disease Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013